Companies Dominating the Conjunctivitis Treatment Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Aurobindo Pharma Limited
- Cipla Limited
- Viatris Inc.
- Akorn Operating Company LLC
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Dr.Reddy’s Laboratories Limited
- MICRO LABS LIMITED
- Ocular Therapeutix, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Conjunctivitis Treatment Market in 2025 is estimated at USD 5.65 billion.
The global market size surpassed USD 5.45 billion in 2024 and is projected to witness a CAGR of over 4.6%, crossing USD 9.78 billion revenue by 2037.
North America is poised to achieve USD 3.52 billion by 2037, fueled by increasing occurrence of conjunctivitis, rising use of corrective lenses, and strong healthcare infrastructure.
The major players in the market include Novartis AG, Aurobindo Pharma Limited, Cipla Limited, Viatris Inc., Akorn Operating Company LLC, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr.Reddy’s Laboratories Limited, MICRO LABS LIMITED, Ocular Therapeutix, Inc.
